Healthcare · NIFTY 500

Neuland Laboratories Limited

NSENEULANDLAB BSE524558 ISININE794A01010 SeriesEQ Listed on NSE · BSE

₹20,923.00 +719.00 (+3.56%) Updated 12 Nov, 7:17 pm IST

Open chart Back to screener

Price, daily close+11.88% in a year

Today

Open: ₹20,204.00
Prev close: ₹20,204.00
Day high: ₹21,102.00
Day low: ₹20,135.00
Volume: 36.5 K
Value traded: ₹75.65 Cr
Upper circuit: ₹24,244.00
Lower circuit: ₹16,164.00
52W high: ₹24,225.00
52W low: ₹11,500.00
1 month: -6.26%
6 months: +12.25%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹26,992 Cr

P/E (TTM)59.32

P/B13.30

Book value / share₹1,573.36

EPS (TTM)₹352.72

ROE22.3%

Dividend yield0.16%

Dividend (12m)₹34.00 / share

Net margin (TTM)19.6%

Operating margin21.7%

Debt / equity0.17

Current ratio2.25

EV / EBITDA38.70

Sales growth (YoY qtr)-12.56%

Profit growth (YoY qtr)—

Sales CAGR 3Y+19.31%

Profit CAGR 3Y+30.57%

Shares1.29 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

3930.0

Dec 23

3850.0

Mar 24

4400.0

Jun 24

3110.0

Sep 24

3980.0

Dec 24

3280.0

Mar 25

29313.9

Jun 25

5140.0

Sep 25

44040.6

Dec 25

776213

Mar 26

642148

Jun 26

45051.6

Sep 26

Revenue · QoQ (vs last quarter)

—-2.0%+14%-29%+28%-18%-11%+76%-14%+77%-17%-30%

Revenue · YoY (vs a year ago)

————+1.3%-15%-33%+65%+10%+136%+119%-13%

Net profit · QoQ (vs last quarter)

———————-100%—+424%-31%-65%

Net profit · YoY (vs a year ago)

——————————+962%—

RevenueNet profitLine = trend

63.44

Dec 23

52.66

Mar 24

76.28

Jun 24

25.60

Sep 24

79.18

Dec 24

21.67

Mar 25

10.83

Jun 25

75.49

Sep 25

31.62

Dec 25

165.76

Mar 26

115.10

Jun 26

40.24

Sep 26

EPS (₹) · YoY (vs a year ago)

————+25%-59%-86%+195%-60%+665%+963%-47%

EPS (₹)Line = trend

₹ Cr	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	393	385	440	311	398	328	293	514	440	776	642	450
Other income	2.1	5.4	4.8	4.3	3.9	7.5	7.9	1.8	8.1	12.5	8.5	7.5
Total income	395	390	444	315	402	336	301	516	448	789	650	457
Raw material	153	175	155	133	145	141	161	228	200	231	229	216
Purchases	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Employee cost	65.7	62.5	73.1	63.1	69.3	66.5	73.5	80.4	88.8	98.5	106	102
Other expenses	63.6	78.1	66.2	68.1	75.7	83.9	71.3	94.7	84.7	101	91.2	99.3
Total expenses	290	298	335	266	330	297	283	387	393	501	452	388
Operating profit	121	107	144	62.2	142	51.1	34.5	156	77.1	307	223	97.6
OPM %	30.9%	27.8%	32.8%	20.0%	35.8%	15.6%	11.8%	30.2%	17.5%	39.6%	34.7%	21.7%
Finance cost	3.7	3.6	2.7	1.1	2.2	2.3	4.6	5.4	6.8	7.2	7.0	7.3
Depreciation	15.1	16.5	16.3	16.1	16.3	16.9	20.2	22.5	23.9	25.1	26.6	28.8
Exceptional items	—	—	20.6	—	55.8	—	—	—	—	—	—	—
Profit before tax	104	92.2	130	49.4	128	39.3	17.6	129	54.5	287	198	69.0
Tax	23.1	24.6	32.0	16.6	26.2	11.5	3.7	32.6	13.9	74.8	50.2	17.4
Net profit	81.4	67.6	97.9	32.8	102	27.8	13.9	96.9	40.6	213	148	51.6
Profit to shareholders	0.0	0.0	0.0	0.0	0.0	0.0	13.9	0.0	40.6	213	148	51.6
EPS (₹)	63.44	52.66	76.28	25.60	79.18	21.67	10.83	75.49	31.62	165.76	115.10	40.24

Profit & loss

Results for each year

7 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

76310216.2

FY20

93714780.6

FY21

95114363.8

FY22

1,191272164

FY23

1,5594630.0

FY24

1,4774000.0

FY25

2,023574364

FY26

Revenue · YoY (vs a year ago)

—+23%+1.5%+25%+31%-5.2%+37%

Net profit · YoY (vs a year ago)

—+397%-21%+156%-100%——

RevenueOperating profitNet profitLine = trend

₹ Cr	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	763	937	951	1,191	1,559	1,477	2,023
Other income	3.9	16.1	2.1	9.7	12.5	20.5	30.2
Total expenses	714	848	871	985	1,170	1,227	1,564
Employee cost	124	150	182	202	257	272	341
Operating profit	102	147	143	272	463	400	574
OPM %	13.4%	15.7%	15.0%	22.8%	29.7%	27.1%	28.4%
Finance cost	21.6	17.9	13.5	13.1	14.0	8.3	23.9
Depreciation	31.3	39.7	49.0	52.8	59.7	65.5	91.7
Profit before tax	52.9	105	82.2	216	401	346	489
Tax	36.7	24.7	18.3	52.2	101	86.2	125
Tax rate %	69.4%	23.5%	22.3%	24.2%	25.2%	24.9%	25.6%
Net profit	16.2	80.6	63.8	164	300	260	364
Profit to shareholders	—	—	—	—	0.0	0.0	364
Net margin %	2.1%	8.6%	6.7%	13.7%	0.0%	0.0%	18.0%
EPS (₹)	12.63	62.85	49.74	127.45	233.89	202.74	283.71

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

99412245.4

Mar 23

1,28382.587.6

Mar 24

1,525136132

Mar 25

1,87419776.7

Mar 26

2,03034253.7

Sep 26

Shareholders' equity · YoY (vs a year ago)

—+29%+19%+23%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	994	1,283	1,525	1,874	2,030
Long-term borrowings	74.2	44.9	90.7	161	296
Short-term borrowings	47.3	37.6	45.3	35.7	46.0
Total borrowings	122	82.5	136	197	342
Current liabilities	439	428	466	710	619
Fixed assets (PPE)	457	523	674	892	994
Inventories	279	350	386	510	552
Trade receivables	362	374	316	541	294
Cash & equivalents	45.4	87.6	132	76.7	53.7
Current assets	761	921	1,139	1,483	1,390
Total assets	1,580	1,833	2,180	2,930	3,030
Debt / equity	0.12	0.06	0.09	0.10	0.17

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

58.6-93.737.7

FY22

237-61.5-136

FY23

261-150-69.3

FY24

317-29825.0

FY25

347-42421.0

FY26

Operations · YoY (vs a year ago)

—+305%+10%+22%+9.2%

OperationsInvestingFinancingLine = trend

₹ Cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	58.6	237	261	317	347
Cash from investing	-93.7	-61.5	-150	-298	-424
Cash from financing	37.7	-136	-69.3	25.0	21.0
Spent on fixed assets	-95.9	-65.7	-141	-206	-390
Free cash flow	-37.3	172	120	111	-43.5
Net cash flow	2.6	39.9	42.2	44.2	-56.1

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

32.8%Dec 23

32.7%Mar 24

32.7%Jun 24

32.6%Sep 24

32.7%Dec 24

32.7%Mar 25

32.7%Jun 25

32.6%Sep 25

32.6%Dec 25

32.6%Mar 26

32.6%Jun 26

32.3%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

32.3%promoter

Promoter & group: 32.26%
Public (FIIs, mutual funds, retail…): 67.74%
Promoter change, last quarter: -0.36 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Dividend - Rs 34 Per ShareEx 24-Jul-2026
Dividend - Rs 12 Per ShareEx 18-Jul-2025
Annual General Meeting/Dividend - Rs 14 Per ShareEx 12-Jul-2024
Annual General Meeting/Dividend - Rs 10 Per ShareEx 11-Jul-2023
Annual General Meeting/Dividend - Rs 5 Per ShareEx 14-Jul-2022
Annual General Meeting/Dividend - Rs 3 Per ShareEx 29-Jun-2021
Interim Dividend - Rs 2 Per ShareEx 10-Nov-2020
Annual General MeetingEx 02-Jul-2020

Board meetings

NEULAND LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited…03-Nov-2026
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 3…03-Nov-2026
NEULAND LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 05-Aug-2026 to inter-alia consider and approve the Unaudited…05-Aug-2026
the financial results for the period ended Jun 30, 202605-Aug-2026
the Yearly Audited Financial results of the Company for the period ended March 2026 and Dividend.12-May-2026

Filings with NSE

Analysts/Institutional Investor Meet/Con. Call Updates6 Nov
Analysts/Institutional Investor Meet/Con. Call Updates6 Nov
Updates5 Nov
Copy of Newspaper Publication4 Nov
Analysts/Institutional Investor Meet/Con. Call Updates3 Nov
Investor Presentation3 Nov
Press Release3 Nov

Latest news

Neuland Laboratories shares surge over 11%, hit record high on strong June quarter earningsUpstox · 6 Aug, 12:30 pm Neuland Laboratories gains after robust quarterly surge and fresh capacity betsIndiatimes · 8 Aug, 12:30 pm Neuland Labs shares surge 10% after Q1 results better analyst expectations, strong commentaryCNBC TV18 · 6 Aug, 12:30 pm Mukul Agrawal portfolio: Neuland Labs soars 10%, hits new high; here's whyBusiness Standard · 6 Aug, 12:30 pm Neuland Laboratories: Betting On New Growth AvenuesBusinessLine · 24 Oct, 9:36 pm Neuland Laboratories Share Price Today: Price Fall AnalysisUnivest · 29 Oct, 12:30 pm Neuland Laboratories shares decline 5% after Q2 results see revenue drop and margin contractionCNBC TV18 · 4 Nov, 1:30 pm Neuland Laboratories' (NSE:NEULANDLAB) five-year total shareholder returns outpace the underlying earnings growthSimply Wall St · 25 Jan, 1:30 pm

About

About Neuland Laboratories Limited

Neuland Laboratories Limited is an Indian publicly listed contract development and manufacturing organization (CDMO) headquartered in Hyderabad. Founded in 1984, the company produces active pharmaceutical ingredients (APIs), advanced intermediates, and peptide APIs. Its shares are traded on the Bombay Stock Exchange and the National Stock Exchange.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Neuland Laboratories Limited
NSE symbol: NEULANDLAB
BSE scrip code: 524558
ISIN: INE794A01010
Listed on: NSE, BSE
Series: EQ (normal equity)
Listed on NSE since: 13 Oct 2008
Face value: ₹10 per share
Market lot: 1 share
Shares issued: 1.29 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Managing director / CEO: Davuluri Saharsh Rao
Chair: Davuluri Rama Mohan Rao
Headquarters: Hyderabad, Telangana, India
Founded: 1984
Employees: 3,881
Financial year: April to March
Results basis: Consolidated
Website: neulandlabs.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Neuland Laboratories Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers